Recent Updates
Recently added Catalysts
EOLS Positive Sentiment

Evolus to Report Second Quarter Financial Results on August 5, 2026

Key Takeaway: Evolus, Inc. has announced that it will report its second quarter financial results for 2026 on August 5, 2026, after market close. A conference call will be held at 4:30 p.m. ET to discuss these results, followed by a Q&A session. Investors can participate via phone or webcast.
Price reaction · baseline $5.805 (2026-07-21 close) · hit pre-market · clean, no other EOLS news in the window
day 0 close · peak
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Evolus is focused on building a strong aesthetic portfolio.
  • The upcoming financial results may indicate growth and performance.
  • Management is engaging with investors through a conference call.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~36 mo
Minimal dilution risk
Lead asset
Botulinum toxin, Type A
Phase 3 · Glabellar Frown Lines

Full Press Release Details

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here .
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13761330. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com .
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse ® , a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo ® , the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at www.evolus.com , and follow us on LinkedIn , X , Instagram or Facebook .
Jeuveau ® , Nuceiva ® , and Evolysse ® are registered trademarks of Evolus, Inc. Profhilo ® is a registered trademark of IBSA Institut Biochimique SA.
Investors: Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications Phone: (248) 202-9267 Email: ir@evolus.com Media: Email: media@evolus.com

Frequently Asked Questions

When will Evolus report its Q2 2026 financial results?

Evolus will report its Q2 2026 financial results on August 5, 2026.

What time is the Evolus conference call?

The conference call will take place at 4:30 p.m. ET on August 5, 2026.

How can I participate in the Evolus conference call?

You can join the call by dialing (877) 407-6184 for U.S. participants or (201) 389-0877 for international callers.

Where can I access the Evolus webcast?

The webcast can be accessed on the Investor Relations page of the Evolus website.

Last updated: Jul 22, 2026